Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

Learn more about:
Related Clinical Trial
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents Intraventricular Stasis In Cardiovascular Disease Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease CorCinch-HF Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy Early Administration of Ivabradine in Children With Heart Failure Metabolomics and Microbiomics in Cardiovascular Diseases Mannheim TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies Risk Stratification in Children and Adolescents With Primary Cardiomyopathy Pediatric Cardiomyopathy Mutation Analysis German Centre for Cardiovascular Research Cardiomyopathy Register Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO An Integrative-“Omics” Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China Metabolomic Study of All-age Cardiomyopathy Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry The Genetics of Cardiomyopathy and Heart Failure Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe Randomized Trial of Interventions to Improve Warfarin Adherence Testing Strategies to Improving Warfarin Adherence Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF) Echo Assessment of Intraventricular Dyssynchrony Brain Function and Perfusion in Patients With Heart Failure Molecular and Imaging Studies of Cardiovascular Health and Disease Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Optimizing Left Ventricular Lead To Improve Cardiac Output Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia. Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure ACC – Atrial Contribution to CRT Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie) Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) Arrhythmia Prediction Trial Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491 Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study. Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure Effect of Rosuvastatin on Left Ventricular Remodeling Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy Assessment of Right Ventricular Function in Advanced Heart Failure An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 Optimized Biventricular Pacing Allograft Recipients BiPAP for Cardiomyopathy With Central Sleep Apnea Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis Effect of Aldosterone on Energy Starvation in Heart Failure Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside Therapy With Verapamil or Carvedilol in Chronic Heart Failure Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure Danish ICD Study in Patients With Dilated Cardiomyopathy Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy DCM Precision Medicine Study A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure Resynchronization Therapy in Young Patients With and Without CHD Withdrawal of Medication in Recovered DCM Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery PUFAs and Left Ventricular Function in Heart Failure 18F-deoxyglucose (FDG) PET-CMD Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Pathophysiology of Dilated Cardiomyopathy Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy Clinical and Genetic Examinations of Dilated Cardiomyopathy Simvastatin Therapy in Patients With Dilated Cardiomyopathy. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Respiratory Muscles Training in Patients With Dilated Cardiomyopathy Myocardial Metabolism in Patients With Dilated Cardiomyopathy Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy Cell Therapy In Dilated Cardiomyopathy Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Nesiritide – Dilated Cardiomyopathy A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy Defining the Role of Insulin Resistance in ‘Idiopathic’ Dilated Cardiomyopathy Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Honey in Idiopathic Dilated Cardiomyopathy A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy

Brief Title

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

Official Title

A Phase 1/2 Trial of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure in Two Stages (Open-Label, Sequential Dose-Escalation Cohorts and Randomized, Double-Blind, Placebo-Controlled, Parallel Cohorts)

Brief Summary

      The study is divided into 2 parts. In the first part, the safety of the gene transfer agent
      MYDICAR® will be evaluated. In the second part, the ability of MYDICAR® to improve heart
      function will be studied.

Detailed Description

      The American Heart Association (AHA) 2006 update on heart disease reported that 5 million
      Americans are believed to have symptomatic heart failure (HF), and 550,000 patients are newly
      diagnosed each year. The estimated direct and indirect cost of HF in the United States (U.S.)
      for 2006 will be ~$29.6 billion. Heart failure is a disabling chronic disease and the most
      frequent discharge diagnosis for hospitalization among older adults. Despite the significant
      resources expended on the treatment of this disease, outcomes remain poor. The five-year
      survival for individuals diagnosed with heart failure is less than 50%, and in end-stage
      heart failure, the one-year survival may be as low as 25% regardless of medical therapy.

      Recent studies suggest that the failing heart is not refractory to treatment, as was
      previously believed. For example, the observation that a small percentage of subjects with
      left ventricular assist devices (LVADs) can be permanently weaned from their device strongly
      suggests that damaged hearts are capable of recovering lost function.

      Clinical studies of MYDICAR® have not yet been conducted in humans. Celladon Corporation
      (Celladon) proposes to investigate gene transfer as a method to restore SERCA2a function in
      heart failure (HF) patients using a recombinant adeno-associated viral vector (AAV), which
      consists of an AAV serotype 1 capsid and contains the human SERCA2a complementary DNA (cDNA)
      flanked by Inverted Terminal Repeats (ITR) derived from AAV serotype 2 (AAV1/SERCA2a).
      MYDICAR® refers to AAV1/SERCA2a drug product intended for administration by percutaneous

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Phase 2: Incidence of Treatment-emergent Adverse Events (TEAE) at 12 Months


Heart Failure, Congestive


MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)

Study Arms / Comparison Groups

 MYDICAR Very Low Dose
Description:  Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) only.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 2007

Completion Date

August 2012

Primary Completion Date

August 2010

Eligibility Criteria

        Inclusion Criteria:

          -  Chronic ischemic or non-ischemic cardiomyopathy. Subjects with ischemic cardiomyopathy
             must have at least one major coronary vessel with Thrombolysis in Myocardial
             Infarction (TIMI) grade 3 flow.

          -  Left ventricular ejection fraction (LVEF) ≤35%

          -  Diagnosis of New York Heart Association (NYHA) Class III/IV heart failure for a
             minimum of 3 months prior to screening

          -  Maximal oxygen consumption (VO2 max) ≤20 mL/kg/min within 90 days prior to enrollment

          -  An implantable cardioverter defibrillator (ICD) implanted a minimum of 30 days prior
             to enrollment

          -  Treatment with appropriate heart failure therapy as tolerated

          -  All women of childbearing potential must have a negative urine pregnancy test prior to
             administration of investigational product and agree to use adequate contraception. Men
             capable of fathering a child must agree to use barrier contraception or limit activity
             to post-menopausal, surgically sterilized, or a contraception-practicing partner, for
             3 months after administration of investigational product.

          -  Ability to sign Informed Consent Form (ICF) and Release of Medical Information Form

        Exclusion Criteria:

          -  Any intravenous therapy with positive inotropes, vasodilators, or diuretics within 30
             days prior to enrollment

          -  Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease,
             amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic
             LV aneurysm

          -  Cardiac surgery, percutaneous coronary intervention, or valvuloplasty within 30 days
             prior to enrollment

          -  Clinically significant myocardial infarction (e.g., ST elevation MI [STEMI] or large
             non-STEMI) within 6 months prior to enrollment

          -  Prior heart transplantation, left ventricular reduction surgery (LVRS),
             cardiomyoplasty, passive restraint device (e.g., CorCap™ Cardiac Support Device),
             surgically implanted LVAD or cardiac shunt

          -  Likely to receive cardiac resynchronization therapy, cardiomyoplasty, LVRS, heart
             transplant, conventional revascularization procedure, or valvular repair within 6
             months following enrollment

          -  Patients with prior coronary artery bypass graft(s) (CABG) will reviewed on a
             case-by-case basis

          -  No evidence of functional or viable myocardium

          -  Exercise capacity primarily limited by obesity, peripheral vascular disease, intrinsic
             pulmonary disease or orthopedic problems and not by underlying heart failure

          -  Known hypersensitivity to octafluoropropane (component of the intravenous
             echocardiography contrast agent, DEFINITY®) or other contrast dyes used for
             angiography; history of, or likely need for, high dose steroid pretreatment prior to
             contrast angiography

          -  A left ventricle that is difficult to image or high quality echocardiography is not
             obtainable at screening

          -  Significant left main or ostial right coronary lumenal stenosis in the opinion of the

          -  Expected survival <1 year in the investigator's medical opinion

          -  Suspected or active viral, bacterial, fungal, or parasitic infection within 48 hours
             prior to enrollment

          -  Liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase
             [AST], alkaline phosphatase) >2x Upper Limit of Normal (ULN) within 30 days prior to
             enrollment or known intrinsic liver disease (e.g., cirrhosis, chronic hepatitis B or
             hepatitis C virus infection)

          -  Current or likely need for hemodialysis within 12 months following enrollment

          -  Bleeding diathesis or thrombocytopenia defined as platelet count <50,000 platelets/μL

          -  Anemia defined as hemoglobin <10 g/dL

          -  Known AIDS or HIV-positive status, or a previous diagnosis of immunodeficiency with an
             absolute neutrophil count <1000 cells/mm3

          -  Previous participation in a study of gene transfer

          -  Presence of neutralizing anti-AAV1 antibodies at titer ≥1:2 within 3 months of

          -  Receiving investigational intervention or participating in another clinical study
             within 30 days or within 5 half-lives of the investigational drug administration prior
             to enrollment

          -  Pregnancy or lactation

          -  Recent history of psychiatric disease (including drug or alcohol abuse) that is likely
             to impair subject's ability to comply with protocol-mandated procedures, in the
             opinion of the investigator

          -  Other concurrent medical condition(s) that, while not explicitly excluded by the
             protocol, could jeopardize the safety of the patient or objectives of the study




18 Years - 75 Years

Accepts Healthy Volunteers



Brian Jaski, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Celladon Corporation

Study Sponsor

Brian Jaski, MD, Principal Investigator, San Diego Cardiac Center

Verification Date

August 2014